Patents Assigned to Ma'at
  • Dimethyl Fumarate and Vaccination Regimens
    Publication number: 20200360501
    Abstract: Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.
    Type: Application
    Filed: December 30, 2019
    Publication date: November 19, 2020
    Applicant: Biogen MA Inc.
    Inventor: Vissia Viglietta
  • Compositions and methods for modulating SMN gene family expression
    Patent number: 10837014
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2 that comprises exon 7. Methods for modulating expression of SMN1 or SMN2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of SMN1 or SMN2.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: November 17, 2020
    Assignee: Translate Bio MA, Inc.
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION
    Publication number: 20200354723
    Abstract: Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).
    Type: Application
    Filed: April 15, 2020
    Publication date: November 12, 2020
    Applicant: Biogen MA Inc.
    Inventor: Eric E. Swayze
  • ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
    Publication number: 20200354459
    Abstract: Antibodies and antigen-binding antibody fragments that bind to GPIIb/IIIa and chimeric polypeptides comprising these binding molecules are disclosed. Some of these antibodies and antigen-binding antibody fragments preferentially bind GPIIb/IIIa on activated platelets while others do not show a preference for binding GPIIb/IIIa on resting versus activated platelets. Some of these antibodies and antibody fragments do not inhibit the interaction of GPIIb/IIIa with fibrinogen, while some others do. The disclosed antibodies do not induce platelet activation. Some of these antibodies and antigen-binding antibody fragments are useful in targeting therapeutic agents such as clotting factors to platelets while others are useful in reducing platelet aggregation and/or thrombus formation.
    Type: Application
    Filed: December 19, 2019
    Publication date: November 12, 2020
    Applicant: Biogen MA Inc.
    Inventors: Bradley Pearse, Joe Salas, Robert Peters, Christilyn Graff
  • Lighting control operating unit having a dual encoder
    Patent number: 10820393
    Abstract: A lighting control operating unit generating digital adjusting commands which are transmitted to a processing unit via a data link includes several control elements, including key buttons, slide controls and/or rotary controls, which are disposed at the upper side of a housing. At least one dual encoder is provided in a control panel of the lighting control operating unit allowing users to enter input values. The dual encoder presents a first shaft rotatably mounted in a housing, and a second shaft mounted in the housing so as to be coaxially rotatable, and corresponding first and second rotation signal generators Both shafts include actuating elements transmitting adjusting movements. The actuating elements are a rotary disk and/or a rotary swivel configured to be coaxially turned in opposite directions.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: October 27, 2020
    Assignee: MA Lighting Technology GMBH
    Inventor: Michael Adenau
  • SP35 Antibodies And Uses Thereof
    Publication number: 20200317775
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: February 13, 2020
    Publication date: October 8, 2020
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber Stark, Steven D. Miklasz, Christilyn Graff
  • Compositions for modulating Tau expression
    Patent number: 10793856
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: October 6, 2020
    Assignee: Biogen MA Inc.
    Inventors: Holly Kordasiewicz, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
  • USE OF LINGO-4 ANTAGONISTS IN THE TREATMENT OF CONDITIONS INVOLVING DEMYELINATION
    Publication number: 20200297800
    Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.
    Type: Application
    Filed: February 5, 2020
    Publication date: September 24, 2020
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, John McCoy
  • Combination Therapies and Uses for Treatment of Demyelinating Disorders
    Publication number: 20200276303
    Abstract: Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments, the methods and compositions described herein include a reparative agent (e.g., a LINGO-1 antagonist) and an immunomodulatory agent, in combination. Thus, methods, compositions and kits described herein can be useful for treating a CNS demyelinating disease.
    Type: Application
    Filed: December 10, 2019
    Publication date: September 3, 2020
    Applicant: Biogen MA Inc.
    Inventors: Diego Cadavid, Sha Mi
  • Hybrid oligonucleotides and uses thereof
    Patent number: 10758558
    Abstract: Provided herein are hybrid oligonucleotides comprising a region that promotes cleavage of a nucleic acid and a region that protects a nucleic acid from exonuclease activity. Such hybrid oligonucleotides are useful for modulating the expression of genes. Related compositions and methods are also provided. In some embodiments, methods are provided for treating a disease, such as by administering a hybrid oligonucleotide.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: September 1, 2020
    Assignee: Translate Bio MA, Inc.
    Inventor: Fatih Ozsolak
  • Biaryl inhibitors of Bruton'S tyrosine kinase
    Patent number: 10759783
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 1, 2020
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Lihong Sun, Lei Zhang, Gnanasambandam Kumaravel, Joseph P. Lyssikatos, Kevin Koch, Hua Miao
  • HUMAN ANTI-TAU ANTIBODIES
    Publication number: 20200262895
    Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: September 24, 2019
    Publication date: August 20, 2020
    Applicants: Biogen MA Inc., Biogen International Neuroscience GmbH
    Inventors: Paul H. Weinreb, Feng Chen, Ellen A. Garber Stark, Jan Grimm, Fabio Montrasio
  • COMPOSITIONS AND METHODS FOR TREATMENT OF STROKE AND OTHER CNS DISORDERS
    Publication number: 20200255530
    Abstract: The invention relates to methods of treating stroke comprising administration of a VLA-4 antagonist to a subject after the onset of the stroke, e.g., ischemic stroke (e.g., acute ischemic stroke) or hemorrhagic stroke (e.g., intracerebral hemorrhage), sub-arachnoid hemorrhage, or traumatic brain injury. Kits and articles of manufacture are also described herein.
    Type: Application
    Filed: July 22, 2016
    Publication date: August 13, 2020
    Applicant: Biogen MA Inc.
    Inventors: Lahar R. MEHTA, Bharath Kumar KANDADI MURALIDHARAN, Jacob ELKINS, Ivan NESTOROV
  • BIOMARKERS FOR USE IN INTEGRIN THERAPY APPLICATIONS
    Publication number: 20200248257
    Abstract: The present invention relates to biomarkers for use in determining the sensitivity of patients to therapy with ?v?6 integrin inhibition or therapy with TGF-? pathway inhibitors. The biomarker profiles disclosed herein provide individualized gene and protein profiles which will aid in treating diseases and disorders which are amenable to treatment with therapies designed against ?v?6-integrin and/or TGF-? pathway inhibitors.
    Type: Application
    Filed: November 14, 2019
    Publication date: August 6, 2020
    Applicants: Biogen MA Inc., The Regents of the University of California
    Inventors: Shelia M. Violette, Dean Sheppard
  • Nuclear transport modulators and uses thereof
    Patent number: 10722497
    Abstract: Compounds of formula I: and pharmaceutically acceptable salts, hydrates, or solvates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using such compounds and compositions to treat various disorders associated with CRM1 activity.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: July 28, 2020
    Assignee: Biogen MA Inc.
    Inventors: Vincent Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu
  • NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
    Publication number: 20200230110
    Abstract: Compounds of formula I: and pharmaceutically acceptable salts, solvates, or hydrates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts, solvates, or hydrates and the compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Application
    Filed: April 6, 2020
    Publication date: July 23, 2020
    Applicant: Biogen MA Inc.
    Inventors: Vincent P. Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu
  • PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
    Publication number: 20200222354
    Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 16, 2020
    Applicant: Biogen MA Inc.
    Inventors: David Goldman, Katherine Dawson, Ajay Nirula
  • LINGO-1 ANTAGONISTS AND USES FOR TREATMENT OF DEMYELINATING DISORDERS
    Publication number: 20200216533
    Abstract: Methods, compositions and kits are described herein useful for detecting and/or treating a CNS demyelinating disease.
    Type: Application
    Filed: October 1, 2019
    Publication date: July 9, 2020
    Applicant: Biogen MA Inc.
    Inventors: Diego Cadavid, Sha Mi
  • Methods and products for evaluating an immune response to a therapeutic protein
    Patent number: 10705095
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: July 7, 2020
    Assignee: BIOGEN MA INC.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • Toy for animals
    Patent number: D898303
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: October 6, 2020
    Assignee: BA.MA. S.P.A.
    Inventor: Renzo Baiocchi